1sthealthcenters - Pediatrics

Meningitis vaccine

Description: 1st Health Centers is conducting a clinical research trial that is investigating the use of a vaccine to prevent against meningitis in the pediatric immunization series.

Qualifications Include:
- Ages 7 months to 9 months, or 12 months old
- Generally healthy

Participation in the study involves two to four follow-up calls. All study-related visits and vaccines will be provided at no cost. Qualified participants will receive compensation for time and travel.

For further information contact our study coordinator at 303-224-4700 or email Lrobinson@1sthealthcenters.com

1st Health Centers
7286 S. Yosemite Street
Suite 180
Centennial, CO 80112
303-224-4700

Click here to volunteer for a research study.

Pediatric Vaccination

Description: 1st Health Centers is currently conducting a clinical research evaluating a meningococcal vaccine for children.

Qualifications Include:
- 2-5 years of age
- Healthy
- Previously received all recommended licensed vaccines
- Available for all study visits and telephone calls

Participation in the study involves 2-3 office visits and 2-3 telephone contacts. All study related vaccines and visits will be provided at no cost. Participants may be compensated for their time and travel.

For further information contact our study coordinator at 303-224-4700 or email Lrobinson@1sthealthcenters.com or Lfriedman@1sthealthcenters.com

1st Health Centers
7286 S. Yosemite Street
Suite 180
Centennial, CO 80112
303-224-4700

Click here to volunteer for a research study.

Gastroesophageal Reflux Disease (GERD)

Description: Gastroesophageal Reflux Disease (GERD) is when stomach contents (stomach acid and/or bile) come back up the esophagus and can cause inflammation or damage to the tissue. This is a result of improper closure of the valve at the top of the stomach.

Current Therapies: Current therapies for this age group include primarily with proton pump inhibitors and H2-blockers. The current therapies are metabolized by a very common pathway and can result in various drug interactions and increased or decreased metabolism of other medications.

Objective: To evaluate the efficacy and safety of an investigational pediatric micro-bead formulation of rabeprazole sodium 2 target dose levels in subjects 1-11 years of age with endoscopically proven GERD.

Study Length: Part 1: 14 weeks, Part 2: 24 weeks

Randomization: Double-blind, randomized to study drug 0.5mg/kg or 1.0mg/kg in a 1:1 ratio

Number of visits: Part 1: 5 in office visits and 2 telephone callsPart 2: 4 in office visits Visit content: Blood draws, pregnancy test (if applicable), EGD with biopsy, pHmetry (if indicated), physical assessments, treatment and symptom surveys/scales

Patient Responsibilities: Patient caregiver must complete an e-diary during the entire study.

Major Inclusions:
- Male or female age 1-11 years
- History of at least 1 GERD symptom within 3 months prior to screening
- Positive EGD during screening

Major Exclusions:
- History of eosinophilic esophagitis
- Have taken PPIs or H2-blockers within 3 days of random assignment
- Have taken sucralfate or any medication affecting GI motility including caffeine within 3 days before study entry
- H.pylori infection
- Current patrticipation or participation in the last 30 days in an investigational drug trial

Participants may receive study medication and physical assessments at no cost during the study. Participants who complete the entire study will be compensated $30 per completed study visit.

For further information contact Laura (303) 224-4694 or Chantal (303)224-4665

1st Health Centers
7286 S. Yosemite Street
Suite 180
Centennial, CO 80112
303-224-4700

Click here to volunteer for a research study.

NEWS:

Download forms prior to your first visit. >>

CONTACT US
Phone: Fax: Email:	(303) 773-9000 or (877) 270-0491 (303) 770-1449 Click here >>
Locations:		South Office >> North Office >>